35 published articles
In GLORY-1, mazdutide 6 mg produced mean body-weight change of approximately negative 15 percent versus negative 0.5 percent with placebo at 48 weeks. The placebo-subtracted treatment difference was approximately negative 14 percentage points. Orforglipron 36 mg achieved approximately negative 12 percent at 72 weeks in ATTAIN-1 but no head-to-head RCT between the two agents exists.
Yes. The EECOH-2 phase 3 trial demonstrated that once-weekly ecnoglutide at both tested doses was non-inferior to dulaglutide in HbA1c reduction over 52 weeks, with the higher dose achieving superiority. The gastrointestinal adverse-event profile was mild-to-moderate and did not exceed dulaglutide rates.
The Phase 3 LUCIDITY trial (NCT06747468), with topline data announced August 18, 2026, showed that avexitide — a first-in-class GLP-1 receptor antagonist — reduced the composite rate of Level 2 and Level 3 hypoglycemic events by 55% versus placebo (p=0.000003) over 16 weeks in adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass. Amylyx plans an NDA by end of 2026.
The 2026 Mateescu Pharmaceutics review (doi:10.3390/pharmaceutics18050625) identifies a fundamental asymmetry in BPC-157's route-of-administration evidence: oral delivery has the strongest mechanistic rationale for gastrointestinal indications because luminal — not systemic — exposure is the therapeutic target, while parenteral routes face a sub-16-minute intravenous half-life and species-variable intramuscular bioavailability (14–51%) that undermine systemic exposure modelling.
The July 23–24, 2026 FDA Pharmacy Compounding Advisory Committee voted 8-6 to recommend BPC-157, KPV, and TB-500 for the 503A Bulks List, and 7-5 for MOTS-c — overriding staff's negative briefing documents. The vote is non-binding; formal rulemaking must follow. Retatrutide was not evaluated under this framework: it is advancing toward a 2027 BLA filing on Phase 3 RCT data.
As of mid-2026, no completed randomized controlled trial has evaluated BPC-157 in any acute human muscle injury indication. The musculoskeletal efficacy record is entirely preclinical. One Phase 2 RCT — NCT07437547, targeting acute grade II hamstring strain — is recruiting, with co-primary endpoints of MRI-assessed injury volume at Day 14 and time to return to unrestricted sport.
Cone snail venom peptides — principally μ-, ω-, and α-conotoxin classes — reduce inflammation-induced pain in vivo through at least three mechanistically distinct pathways: voltage-gated sodium channel (NaV1.7/NaV1.8) blockade that silences peripheral nociceptor firing, N-type calcium channel (CaV2.2) inhibition that curtails spinal neurotransmitter release, and suppression of the NF-κB/COX-2 axis that drives prostaglandin-mediated peripheral sensitisation.
VRB-103 is a once-weekly oral amylin analog entering Phase 1 development by Verdiva Bio, with first-patient dosing confirmed in late July 2026. Whether it reproduces injectable-style weight-loss efficacy depends on three unresolved variables: oral bioavailability at therapeutically relevant concentrations, retention of AMY receptor selectivity after structural modification, and a tolerability profile that improves on pramlintide's nausea burden.
As of mid-2026, TB-500's wound-healing evidence base is mechanistically coherent and preclinically robust, but no completed human randomised controlled trial has evaluated the compound in any wound-healing indication. The July 2026 FDA PCAC review identified this absence as the definitive barrier to 503A compounding eligibility. The human trial gap is not narrowing — it remains structurally unbridged.
The TRIUMPH-1 topline readout — the primary obesity-without-diabetes arm of retatrutide's phase III programme — reports mean body-weight reductions of approximately 19% at 4 mg, 24% at 8 mg, and 28% at 12 mg over 80 weeks versus placebo. Cardiometabolic endpoints show dose-proportional improvements. The 80-week timepoint is the longest placebo-controlled pharmacological weight-loss dataset for any triple agonist in 2026.
Both GIPR agonism and GIPR antagonism reduce body weight in preclinical models, creating a pharmacological paradox unresolved as of 2026. GIPR agonism in hypothalamic neurons suppresses food intake, while GIPR antagonism in peripheral adipose tissue blocks lipid storage. Tirzepatide's clinical success as a GIPR agonist does not invalidate the antagonist data — it reflects a different mechanistic axis.
Phase II data for sonefpeglutide — a long-acting GLP-1/GIP/glucagon triple receptor co-agonist — demonstrate clinically meaningful reductions in hepatic steatosis, NAS score components, and fibrosis stage in biopsy-confirmed MASH. MRI-PDFF liver-fat reduction exceeded 50% relative from baseline at the highest doses, and a substantial proportion of participants achieved MASH resolution without fibrosis worsening, meeting the FDA's accepted surrogate histological endpoint.